Catalent reports 13% revenue jump in Q4; Central Europe CRO market to grow 7% a year;

> Catalent's fourth-quarter revenue spiked 13% to $478 million, thanks largely to its February acquisition of Aptuit. Report

> CROs in Central Europe have been fighting for market share of late, and a new report says the clinical trial market there will grow by about 7% per year through 2014. More

> China's WuXi PharmaTech has signed a deal to manufacture the HIV drug ibalizumab for TaiMed Biologics. News

> The Regulatory Affairs Professionals Society says CROs in emerging markets can benefit from taking the organization's test, bringing them up to speed on regulatory requirements around the world. Article

> CMC Biologics has appointed a new general manager for its Denmark CMO facility, tapping Patricio Massera to head the plant. Story

> The progress of personalized medicine suggest that whether or not a treatment is effective is based on a complex network of varying genes, flying in the face of the FDA's methods of isolating variables in clinical trials. What does that mean for the future of drug research? Item

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

WCG is continuing its buyout run after acquiring clinical trial solutions firm Trifecta Clinical.

London-based uMed has raised nearly $4.8 million from U.K. and U.S. VCs to help healthcare providers participate in more clinical studies.

Amgen has teamed up with cloud-based trial solutions firm Reify Health to help boost patients into its drug studies.